SCHEMBL17951090

SCHEMBL17951090

CC1CCC2CN1N(c1ncnc3[nH]ccc13)C2=O

nearest known ligand 0.61

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ JAK3 P52333 13/20 0.61
▸ LCK P06239 1/20 0.52
▸ AKT2 P31751 2/20 0.47
▸ GSK3B P49841 2/20 0.47
▸ KIT P10721 1/20 0.47
▸ DOT1L Q8TEK3 2/20 0.46
▸ JAK1 P23458 3/20 0.44
▸ TEC P42680 1/20 0.44
▸ TXK P42681 1/20 0.44
▸ BLK P51451 1/20 0.44
▸ BMX P51813 1/20 0.44
▸ BTK Q06187 1/20 0.44
▸ ITK Q08881 1/20 0.44
▸ ERBB4 Q15303 1/20 0.44
▸ JAK2 O60674 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3960604 0.76 JAK3 (1.00) JAK3LCKAKT2GSK3BKIT
SCHEMBL3956876 0.71 JAK3 (0.89) JAK3LCKAKT2GSK3BKIT
SCHEMBL2024604 0.69 JAK3 (1.00) JAK3LCKAKT2GSK3BKIT
SCHEMBL10079358 0.69 JAK3 (1.00) JAK3LCKAKT2GSK3BKIT
SCHEMBL2021330 0.69 JAK3 (1.00) JAK3LCKAKT2GSK3BKIT
SCHEMBL2019457 0.69 LCK (1.00) JAK3LCKAKT2GSK3BKIT
SCHEMBL3952874 0.69 JAK3 (0.75) JAK3LCKAKT2GSK3BKIT
SCHEMBL2016053 0.69 JAK3 (1.00) JAK3LCKAKT2GSK3BKIT
SCHEMBL3953429 0.68 JAK3 (0.65) JAK3LCKAKT2GSK3BKIT
SCHEMBL3954391 0.68 JAK3 (1.00) JAK3LCKAKT2GSK3BKIT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3248980-B1 JAK INHIBITOR WUXI FORTUNE PHARMACEUTICAL CO LTD (CN) 2023-09-06 — — EP disclosed
US-10617690-B2 JAK inhibitor Wuxi Fortune Pharmaceutical Co., Ltd (CN) 2020-04-14 — — US disclosed
US-20170360794-A1 JAK INHIBITOR Wuxi Fortune Pharmaceutical Co., Ltd (CN) 2017-12-21 — — US disclosed
US-20170360794-A1 JAK INHIBITOR Wuxi Fortune Pharmaceutical Co., Ltd (CN) 2017-12-21 — — US disclosed
US-20170360794-A1 JAK INHIBITOR Wuxi Fortune Pharmaceutical Co., Ltd (CN) 2017-12-21 — — US disclosed
EP-3248980-A1 JAK INHIBITOR Wuxi Fortune Pharmaceutical Co., Ltd (CN) 2017-11-29 — — EP disclosed
WO-2016116025-A1 JAK INHIBITOR 南京明德新药研发股份有限公司 2016-07-28 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170360794-A1 JAK INHIBITOR JAK2, JAK1, JAK3 JAK3 3/4885LCK 15/4885AKT2 540/4885
US-10617690-B2 JAK inhibitor JAK2, JAK1, JAK3 JAK3 3/4885LCK 15/4885AKT2 540/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback